Insider · CIK 0002034671
Claire Mazumdar
directorceoofficer
Files at RLAY (Relay Therapeutics, Inc.), BCAX (Bicara Therapeutics Inc.). First filing Oct 15, 2025, latest Mar 20, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 6
$0 bought, $2.8M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BCAX: Bicara Therapeutics Inc.
BCAXOct 9, 2026 · close 17.50
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | Bicara Therapeutics Inc. | $282k 15,000 shares | -4% | +111% from low-8% from high | |
| 26Weak | Bicara Therapeutics Inc. | $705k 36,766 shares | -10% | +126% from low0% from high | |
| 16Weak | Bicara Therapeutics Inc. | $154k 8,234 shares | -2% | +113% from low-3% from high | |
| 32Weak | Bicara Therapeutics Inc. | $776k 41,163 shares | -12% | +117% from low-11% from high | |
| 22Weak | Bicara Therapeutics Inc. | $454k 24,103 shares | -7% | +114% from low-26% from high | |
| 22Weak | Bicara Therapeutics Inc. | $467k 24,734 shares | -8% | +113% from low-27% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +6,499 | $3.79 | $25k | 345,891 | Mar 20, 2026 |
| Mar 18, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -6,499 | $18.84 | $122k | 339,392 | Mar 20, 2026 |
| Mar 19, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +6,905 | $3.79 | $26k | 346,297 | Mar 20, 2026 |
| Mar 19, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -6,905 | $18.78 | $130k | 339,392 | Mar 20, 2026 |
| Mar 20, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +1,596 | $3.79 | $6,049 | 340,988 | Mar 20, 2026 |
| Mar 20, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -1,596 | $18.95 | $30k | 339,392 | Mar 20, 2026 |
| Mar 18, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,499 | $0.00 | $0 | 184,608 | Mar 20, 2026 |
| Mar 19, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,905 | $0.00 | $0 | 177,703 | Mar 20, 2026 |
| Mar 20, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,596 | $0.00 | $0 | 176,107 | Mar 20, 2026 |
| Mar 9, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +36,766 | $3.79 | $139k | 376,158 | Mar 11, 2026 |
| Mar 9, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -36,766 | $19.17 | $705k | 339,392 | Mar 11, 2026 |
| Mar 9, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -36,766 | $0.00 | $0 | 191,107 | Mar 11, 2026 |
| Mar 4, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +2,631 | $3.79 | $9,971 | 342,023 | Mar 6, 2026 |
| Mar 4, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -2,631 | $18.73 | $49k | 339,392 | Mar 6, 2026 |
| Mar 5, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +1,786 | $3.79 | $6,769 | 341,178 | Mar 6, 2026 |
| Mar 5, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -1,786 | $18.74 | $33k | 339,392 | Mar 6, 2026 |
| Mar 6, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +3,817 | $3.79 | $14k | 343,209 | Mar 6, 2026 |
| Mar 6, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -3,817 | $18.75 | $72k | 339,392 | Mar 6, 2026 |
| Mar 4, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,631 | $0.00 | $0 | 233,476 | Mar 6, 2026 |
| Mar 5, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,786 | $0.00 | $0 | 231,690 | Mar 6, 2026 |
| Mar 6, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,817 | $0.00 | $0 | 227,873 | Mar 6, 2026 |
| Feb 2, 2026 | BCAX Bicara Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +450,000 | $0.00 | $0 | 450,000 | Feb 4, 2026 |
| Dec 16, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock | +29,500 | $5.45 | $161k | 339,392 | Dec 18, 2025 |
| Dec 16, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative | -29,500 | $0.00 | $0 | 565,512 | Dec 18, 2025 |
| Nov 24, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +41,163 | $3.79 | $156k | 351,055 | Nov 25, 2025 |
| Nov 24, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -41,163 | $18.86 | $776k | 309,892 | Nov 25, 2025 |
| Nov 24, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -41,163 | $0.00 | $0 | 236,107 | Nov 25, 2025 |
| Oct 16, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +24,103 | $3.79 | $91k | 333,995 | Oct 20, 2025 |
| Oct 16, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -24,103 | $18.83 | $454k | 309,892 | Oct 20, 2025 |
| Oct 16, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -24,103 | $0.00 | $0 | 277,270 | Oct 20, 2025 |
| Oct 13, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +11,445 | $3.79 | $43k | 321,337 | Oct 15, 2025 |
| Oct 13, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -11,445 | $18.92 | $217k | 309,892 | Oct 15, 2025 |
| Oct 15, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +13,289 | $3.79 | $50k | 323,181 | Oct 15, 2025 |
| Oct 15, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -13,289 | $18.84 | $250k | 309,892 | Oct 15, 2025 |
| Oct 13, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,445 | $0.00 | $0 | 314,662 | Oct 15, 2025 |
| Oct 15, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -13,289 | $0.00 | $0 | 301,373 | Oct 15, 2025 |
| Jun 9, 2025 | RLAY Relay Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +421,241 | $0.00 | $0 | 421,241 | Jun 11, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.